Richard Scott Struthers - 07 Aug 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Reporting relationship
President & CEO, Director
Issuer ticker
CRNX
Reported as of
07 Aug 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
11 Aug 2026, 16:11:18 UTC
Prior SEC filing
02 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Tobin Schilke, as attorney-in-fact

Key filing fact

Richard Scott Struthers filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 11 Aug 2026.

Key facts

  • This page summarizes Richard Scott Struthers's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
  • 8 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 11 Aug 2026, 16:11.

Change

  • Previous filing in this sequence was filed on 02 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001746298 Primary reporting owner

Struthers Richard Scott

Relationship
President & CEO, Director
Address
C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO
Signature
/s/ Tobin Schilke, as attorney-in-fact
Signature date
11 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRNX transaction

Common Stock

Options Exercise

Transaction value
Shares
+3,969
Change %
+0.98%
Price
$25.19*
Shares after
408,747
Date
07 Aug 2026
Ownership
Direct
CRNX transaction

Common Stock

Options Exercise

Transaction value
Shares
+4,422
Change %
+1.1%
Price
$22.61*
Shares after
413,169
Date
07 Aug 2026
Ownership
Direct
CRNX transaction

Common Stock

Options Exercise

Transaction value
Shares
+6,542
Change %
+1.6%
Price
$15.29*
Shares after
419,711
Date
07 Aug 2026
Ownership
Direct
CRNX transaction

Common Stock

Options Exercise

Transaction value
Shares
+4,995
Change %
+1.2%
Price
$20.02*
Shares after
424,706
Date
07 Aug 2026
Ownership
Direct
CRNX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
136,805
Date
07 Aug 2026
Ownership
By Family Trust 1
CRNX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
106,000
Date
07 Aug 2026
Ownership
By Family Trust 2
CRNX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
110,000
Date
07 Aug 2026
Ownership
By Family Trust 3
CRNX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
100,000
Date
07 Aug 2026
Ownership
By Family Trust 4
CRNX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
111,100
Date
07 Aug 2026
Ownership
By Family Trust 5
CRNX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
111,100
Date
07 Aug 2026
Ownership
By Family Trust 6
CRNX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
111,100
Date
07 Aug 2026
Ownership
By Family Trust 7
CRNX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
111,100
Date
07 Aug 2026
Ownership
By Family Trust 8
CRNX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,000
Date
07 Aug 2026
Ownership
By Spouse
CRNX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
80,000
Date
07 Aug 2026
Ownership
By Charitable Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRNX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-3,969
Change %
-2.3%
Price
$0.000000*
Shares after
172,281
Date
07 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,969
Exercise price
$25.19
Footnotes
F1
CRNX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-4,422
Change %
-2.2%
Price
$0.000000*
Shares after
195,578
Date
07 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,422
Exercise price
$22.61
Footnotes
F2
CRNX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-6,542
Change %
-2.5%
Price
$0.000000*
Shares after
259,058
Date
07 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,542
Exercise price
$15.29
Footnotes
F3
CRNX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-4,995
Change %
-2%
Price
$0.000000*
Shares after
244,205
Date
07 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,995
Exercise price
$20.02
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

1/48th of the shares subject to the option vested monthly.

Footnote F2

1/48th of the shares subject to the option vested on March 24, 2020, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Footnote F3

1/48th of the shares subject to the option vested on March 26, 2021, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Footnote F4

1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .